Method Of Cancer Diagnosis Using The Analysis Of Isotopes

Abstract

Disclosed is a method of diagnosing cancer on the basis of the quantitative analysis of blood or tissue isotopes, for example, such as .sup.36S or .sup.40K. The method can accurately diagnose cancer in a patient even when it is too small for current conventional technology to diagnose.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation application under the provisions of 35 U.S.C. .sctn. 120 of U.S. patent application Ser. No. 12/674,425 filed Feb. 20, 2010, which is a U.S. national phase application under the provisions of 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/KR2007/005088 filed Oct. 17, 2007, which in turn claims priority of Korean Patent Application No. 10-2007-0085873 filed Aug. 27, 2007.

[0002] The disclosures of such U.S. and international patent applications and Korean priority patent application are hereby incorporated herein by reference in their respective entireties, for all purposes.

TECHNICAL FIELD

[0003] The present invention relates, in general, to cancer diagnosis and, more particularly, to a method for diagnosing cancer on the basis of quantitative analysis of isotopes of blood or tissue samples, which is able to accurately detect cancer even when it is too small to be detected with conventional technologies.

BACKGROUND ART

[0004] Isotopes are any of several different forms of an element each having a different atomic mass (mass number). The term "isotope", coined by British chemist F. Soddy in 1913, comes from the Greek isos "equal"+topos "place," because despite the different atomic weights, the various forms of an element occupy the same place on the periodic table.

[0005] Generally, the chemical properties of an element depend on the number of protons, that is, the atomic number. Isotopes of an element have nuclei having the same number of protons (the same atomic number) but different numbers of neutrons. Therefore, isotopes have different mass numbers, which indicate the total number of nucleons-the number of protons plus neutrons. For example, oxygen occurs in nature as three different isotopes, each with 8 protons. The most common isotope is .sup.16O (8 protons, 8 neutrons), which constitutes more than 99% of all oxygen atoms on earth. There is also the rare isotope .sup.18O (10 neutrons) and the even rarer isotope .sup.17O (9 neutrons). Nitrogen exists as two stable isotopes, .sup.14N and .sup.18N, in nature. Naturally occurring uranium is composed of three major isotopes, uranium-238, uranium-235, and uranium-234.

[0006] Because there are the same numbers of electrons as protons in an element, isotopes of an element are identical in the number of electrons. Approximately 90 elements exist in nature, and there are as many as about 300 naturally occurring isotopes, with an average of 3 isotopes per element. In fact, tin (Sn) is the element with the greatest number of stable isotopes (ten), and cadmium has the second highest number of isotopes (eight) while there are elements that exist as only one isotope in nature, such as beryllium, fluorine, sodium and bismuth.

[0007] There is no general rule for relationship between a naturally occurring element and the number of stable isotopes thereof. However, it has been observed that most of the elements that have odd atomic numbers each have two or fewer isotopes, whereas individual elements with even atomic numbers have relatively many isotopes. A naturally occurring element is a mixture of isotopes with almost the same ratios therebetween or thereamong in any sample of the earth. In general, the atomic weight of an element is the average of the atomic masses of all the chemical element's isotopes as found in a particular environment, weighted by isotopic abundance. The reason why a majority of atomic weights are not integers or near-integers but decimals is that most elements are assemblages of isotopes. For a short-hand designation of different isotopes (also called nuclides), the mass number (number of nucleons) is written in the right position or in the upper left corner of the chemical symbol, like oxygen-16, .sup.16O, nitrogen-14 .sup.14N, uranium-235 .sup.228U, etc. Particularly as for hydrogen isotopes, specific names are given thereto, such as protium for H-1, deuterium for H-2, and tritium for H-3.

[0008] Recent studies have showed that the oxygen isotope .sup.18O is toxic to organisms. Deuterium .sup.2H in the form of D.sub.2O was found to have 92% inhibitory activity against microorganisms and to kill rats at a rate of 99.5% within 5 days.

[0009] High prevalence rates of cancer are reported in radioactive contamination area, implying that persons excessively exposed to radioactive radiation may increase in isotope level in their bodies and may be liable to affliction with cancer.

[0010] Leading to the present invention, intensive and thorough research into the treatment and diagnosis of cancer, conducted by the present inventor, resulted in the finding that cancer can be caused with a change in blood isotope level and that the incidence and kind of cancer can be diagnosed through the quantitative analysis of blood or tissue isotopes.

DISCLOSURE

Technical Problem

[0011] The present invention pertains to cancer diagnosis through the analysis of blood or tissues for isotope content.

[0012] It is difficult for even up-to-date scientific technology to accurately diagnose tumors less than 1 mm in size. However, blood analysis according to the present invention can provide a basis or criteria with which accurate diagnosis can be achieved for the incidence and kind of cancer in an early stage, thus giving rise to an increase in the probability of successful cancer treatment. Therefore, it is an object of the present invention to provide a method of diagnosing cancer by analyzing blood or tissue isotope levels and comparing them with those of normal persons.

Technical Solution

[0013] In order to accomplish the above object, the present invention provides a method of diagnosing cancer, comprising measuring levels of isotopes of an element in a blood sample or a tissue sample.

[0014] In accordance with a modification thereof, the element is selected from a group consisting of hydrogen, oxygen, magnesium, calcium, potassium, sulfur, chloride, silicon, iron, copper, and combinations thereof.

[0015] In accordance with another modification thereof, the method is based on an increase in the level of deuterium (.sup.CH) by 10% or higher compared to a normal standard.

[0016] In accordance with a further modification, the method is based on an increase in the level of .sup.18O by 10% or higher, compared to a normal standard.

[0017] In accordance with still a further modification, the method is based on an increase in the level of a heavy isotope of the element compared to a normal standard.

[0018] In accordance with still another modification, the method is based on the depletion of .sup.40K and/or .sup.36S from the sample.

Advantageous Effects

[0019] Featuring the quantitative analysis of blood or tissue isotopes, the present invention can accurately diagnose cancer even when it is too small for current conventional technology to diagnose. Hence, the present invention can make a great contribution to the treatment of cancer and provide an opportunity for cancer patients to recover from the disease and lead a healthy life. It is well known that when cancer is diagnosed in its early stage, it can be cured at a high success rate. However, diagnosis methods that can detect even small cancers with certainty have not been developed yet. The present invention, which overcomes the limitation of the prior art methods, can detect cancer in the early stage thereof and thus allow cancer to be successfully cured.

Best Mode

[0020] Prior to entry into the detailed description of the present invention, it should be noted that a description of well-known functions or constitutions in conjunction with the present invention will be omitted in order to make the gist of the present invention unambiguous.

[0021] In the present invention, distilled water, mineral water, electrolysed water, and blood and tissues from healthy persons and cancer patients are qualitatively and quantitatively analyzed for isotopes. An example of an instrument for use in the isotope analysis includes EMAL-2 (Energy Mass Analyzer), which is a double-focus type mass spectrophotometer. Individual ions are used as laser sources for atomic ionization and vaporization.

[0022] A standard sample is used to correct the analysis results. In this regard, 10 elements, including magnesium, silicon, sulfur, chloride, potassium, calcium, chrome, iron, copper, hydrogen, and oxygen, are employed and analyzed for compositions in various samples. Stable isotopes analyzed in the present invention have mass numbers 24, 25 and 26 for the element magnesium, mass numbers 28, 29 and 30 for the element silicon, mass numbers 32, 33, 34 and 36 for the element sulfur, mass numbers 35 and 37 for the element chloride, mass numbers 39, 40 and 41 for the element potassium, mass numbers 40, 42, 43, 44, 46 and 48 for the element calcium, mass numbers 50, 52, 53 and 54 for the element chrome, mass numbers 54, 56, 57 and 58 for the element iron, and mass numbers 63 and 65 for the element copper. Prior to isotope analysis, all samples except for water are dried at 360.degree. C. for 1 hour in a vacuum oven.

[0023] SMOW (Standard Mean Ocean Water), which serves as a reference standard for comparing hydrogen and oxygen isotope ratios, mostly in water samples, is also used in the present invention. The isotope composition of oxygen and hydrogen in a sample is expressed as per mil (% thousand) differences relative to SMOW. 4-5 ml of water is reacted with uranium at 800.degree. C. in a vacuum of 10.sup.-5-10.sup.-6 mmHg to generate hydrogen atoms for use in the measurement.

[0024] An instrument suitable for analyzing the isotope compositions of hydrogen includes a Varian GD 150 isotope ratio mass spectrometer while the isotope compositions of oxygen in water and in gas phase samples are analyzed using an Electron spectrometer (Sumi, Ukraine). These spectrometers can detect very small changes in the isotope compositions of individual elements and analyze samples and a standard simultaneously. The mass spectrometer is equipped with 2 or 3 ion collectors and can measure 2-3 ion currents at the same time and analyze the relationship therebetween. The isotope compositions of elements in blood samples are analyzed using EMAL-2.

MODE FOR INVENTION

[0025] A better understanding of the present invention may be obtained through the following examples which are set forth to illustrate, but are not to be construed as the limit of the present invention.

EXAMPLE 1

Deuterium Level in Blood

[0026] Deuterium content was expressed as ppm relative to protium content. Listed in Table 1 are the numbers of .sup.2D per 1,000,000 .sup.1H.

TABLE-US-00001 TABLE 1 Blood Samples D/H (in ppm) Normal 126 Stomach Cancer Patient 147 Liver Cancer Patient 147.5 Lung Cancer Patient 148.2 Breast Cancer Patient 147.6 Leukemia Patient 148.2

[0027] Cancer patients were measured to have a 15.about.20% increase in the blood level of deuterium, compared to normal persons.

EXAMPLE 2

.sup.18O Level in Blood

[0028] The oxygen isotope .sup.18O content was expressed as ppm relative to the oxygen isotope .sup.16O content. Listed in Table 2 are the numbers of .sup.18O per 1,000,000 .sup.16O.

TABLE-US-00002 TABLE 2 Blood Samples .sup.18O/.sup.16O (in ppm) Normal 1430 Stomach Cancer Patient 1998 Liver Cancer Patient 1995 Lung Cancer Patient 1994 Breast Cancer Patient 1996 Leukemia Patient 1995.5

[0029] Cancer patients were measured to have an about 35.about.40% increase in the blood level of .sup.18O, compared to normal persons.

EXAMPLE 3

Comparison of Levels of Magnesium Isotopes in Blood

[0030] In Table 3, below, the measurements of blood magnesium isotope content using a mass spectrometer were expressed in arbitrary units.

TABLE-US-00003 TABLE 3 Blood Samples .sup.24M .sup.25M .sup.26M Normal 72.1 7.2 9.1 Stomach Cancer Patient 69.5 9.5 23.2 Liver Cancer Patient 45.2 9.6 45.5 Lung Cancer Patient 55.1 9.5 41.0 Breast Cancer Patient 55.6 15.2 33.2 Leukemia Patient 40.2 8.5 52.6

[0031] The levels of heavy isotopes in the blood were measured to be significantly increased in cancer patients, compared to normal persons.

EXAMPLE 4

Comparison of Levels of Silicon Isotopes in Blood

[0032] In Table 4, below, the measurements of blood silicon isotope content using a mass spectrometer are expressed in arbitrary units.

TABLE-US-00004 TABLE 4 Blood Samples .sup.28Si .sup.29Si .sup.30Si Normal 55.2 10.5 2.2 Stomach Cancer Patient 65.3 25.7 8.6 Liver Cancer Patient 49.9 39.5 12.5 Lung Cancer Patient 59.4 33.4 13.6 Breast Cancer Patient 65.8 30.2 8.6 Leukemia Patient 65.3 25.6 10.5

[0033] The levels of heavy isotopes in the blood were measured to be significantly increased in cancer patients, compared to normal persons.

EXAMPLE 5

Comparison of Levels of Iron Isotopes in Blood

[0034] In Table 5, below, the measurements of blood iron isotope content using a mass spectrometer are expressed in arbitrary units.

TABLE-US-00005 TABLE 5 Blood Samples .sup.54Fe .sup.56Fe .sup.57Fe .sup.58Fe Normal 3.2 58 14.1 2.1 Stomach Cancer Patient 3.6 68 25.1 3.3 Liver Cancer Patient 3.7 59 35.2 3.8 Lung Cancer Patient 4.1 63 28.5 3.5 Breast Cancer Patient 4.2 52 32.4 4.2 Leukemia Patient 4.2 60.5 31.5 3.5

[0035] The levels of heavy isotopes in the blood were measured to be significantly increased in cancer patients, compared to normal persons.

EXAMPLE 6

Comparison of Levels of Copper Isotopes in Blood

[0036] In Table 6, below, the measurements of blood copper isotope content using a mass spectrometer are expressed in arbitrary units.

TABLE-US-00006 TABLE 6 Blood Samples .sup.63Cu .sup.65Cu Normal 65 35 Stomach Cancer Patient 72 28 Liver Cancer Patient 63 41 Lung Cancer Patient 61 42 Breast Cancer Patient 60 35 Leukemia Patient 74 25

[0037] There were no significant differences in light isotope levels between cancer patients and normal persons.

EXAMPLE 7

Comparison of Levels of Sulfur Isotopes in Blood

[0038] In Table 7, below, the measurements of blood sulfur isotope content using a mass spectrometer are expressed in arbitrary units.

TABLE-US-00007 TABLE 7 Blood Samples .sup.32S .sup.33S .sup.34S .sup.36S Normal 55.5 20.1 2.3 1.1 Stomach Cancer Patient 62.1 25.5 9.5 0 Liver Cancer Patient 52.1 35.5 12.3 0 Lung Cancer Patient 58.9 26.5 13.2 0 Breast Cancer Patient 66.6 31.2 7.8 0 Leukemia Patient 61.2 25.9 10.3 0

[0039] The cancer patients were found to have a higher level of the heavy isotope than were normal persons. As for .sup.36S, however, it was not detected in cancer patients, indicating that patients suffering from cancer lack the isotope.

EXAMPLE 8

Comparison of Levels of Chloride Isotopes in Blood

[0040] In Table 8, below, the measurements of blood chloride isotope content using a mass spectrometer are expressed in arbitrary units.

TABLE-US-00008 TABLE 8 Blood Samples .sup.35Cl .sup.37Cl Normal 60.2 25.3 Stomach Cancer Patient 72.3 25.7 Liver Cancer Patient 71.5 28.8 Lung Cancer Patient 68.2 26.5 Breast Cancer Patient 77.5 21.3 Leukemia Patient 63.2 32.1

[0041] The overall levels of heavy isotopes in the blood were observed to be higher in cancer patients compared to normal persons.

EXAMPLE 9

Comparison of Levels of Potassium Isotopes in Blood

[0042] In Table 9, below, the measurements of blood potassium isotope content using a mass spectrometer were expressed in arbitrary units.

TABLE-US-00009 TABLE 9 Blood Samples .sup.39K .sup.40K .sup.41K Normal 79.5 1.2 6.3 Stomach Cancer Patient 86.4 0 10.5 Liver Cancer Patient 82.3 0 18.5 Lung Cancer Patient 94.3 0 6.5 Breast Cancer Patient 77.5 0 16.2 Leukemia Patient 88.6 0 11.1

[0043] Of the potassium isotopes, .sup.40K was measured to be zero in cancer patients, which distinguishes cancer patients from normal persons. The heavy isotope was measured at higher levels in cancer patients than in normal patients.

EXAMPLE 10

Comparison of Levels of Calcium Isotopes in Blood

[0044] In Table 10, below, the measurements of blood calcium isotope content using a mass spectrometer was expressed in arbitrary units.

TABLE-US-00010 TABLE 10 Blood Samples .sup.40Ca .sup.42Ca .sup.43Ca .sup.44Ca .sup.46Ca .sup.48Ca Normal 57.4 1.2 2.3 1.7 0.2 0.15 Stomach Cancer Patient 66.8 3.4 9.5 6.7 5.7 1.6 Liver Cancer Patient 31.5 6.4 25.6 27.4 15.3 1.5 Lung Cancer Patient 54.2 4.6 18.7 17.5 7.6 1.2 Breast Cancer Patient 51.2 4.3 18.6 17.9 7.8 1.8 Leukemia Patient 34.5 5.6 19.4 24.6 15.6 1.1

[0045] The heavy isotopes of element calcium were measured at higher levels in cancer patients than in normal persons.

[0046] Taken together, the data obtained in the above examples demonstrate that the analysis of isotope levels in blood or tissues can be used to determine the incidence of cancer, particularly based on an increase in isotope levels or the depletion of .sup.40K or .sup.36S.

[0047] Although the preferred embodiment(s) of the present invention have(has) been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.

Claims

1. A method of diagnosing cancer in a patient, comprising (a) measuring the level of isotope .sup.40K in a blood sample or a tissue sample of the patient by using a double-focus type mass spectrophotometer; (b) measuring the level of Deuterium .sup.2D or .sup.18O in a blood sample or a tissue sample of the patient using a double-focus type mass spectrophotometer; (c) diagnosing cancer in the patient if (i) .sup.40K is not detected and (ii) if the level of the .sup.2D or .sup.18O isotope is greater than the level of a normal standard for the .sup.2D or .sup.18O isotope.

2. The method according to claim 1, wherein the method comprises measuring the level of deuterium .sup.2D in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.2 times increased level of .sup.2D is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.2D isotope, or the method comprises measuring the level of .sup.18O in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.4 times increased level of .sup.18O is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.18O isotope.

3. The method according to claim 1, wherein the method further comprises measuring the level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if an increased level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes is detected in the blood sample or tissue sample of the patient compared to a normal standard for the isotope.

4. The method according to claim 3, wherein the method comprises measuring the level of sulfur isotope .sup.33S or .sup.34S in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.3 times increased level of .sup.33S or .sup.34S is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.33S or .sup.34S.

5. The method according to claim 3, wherein the method comprises measuring the level of .sup.26Mg in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.5 times increased level of .sup.26Mg is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.26Mg.

6. The method according to claim 3, wherein the method comprises measuring the level of .sup.29Si or .sup.30Si in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.4 times increased level of .sup.29Si or .sup.30Si is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.29Si or .sup.30Si.

7. The method according to claim 3, wherein the method comprises measuring the level of .sup.57Fe or .sup.58Fe in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 1.6 times increased level of .sup.57Fe or .sup.58Fe is detected in the blood sample or tissue sample of the patient compared to a normal standard for .sup.57Fe or .sup.88Fe.

8. The method according to claim 3, wherein the method comprises measuring the level of at least one of the calcium isotopes .sup.42Ca, .sup.43Ca, .sup.44Ca, .sup.46Ca and .sup.48Ca in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if more than 2.8 times increased level of at least one of the calcium isotopes .sup.42Ca, .sup.43Ca, .sup.44Ca, .sup.46Ca and .sup.48Ca is detected in the blood sample or tissue sample of the patient compared to a normal standard for the at least one of the calcium isotopes 42Ca, .sup.43Ca, .sup.44Ca, .sub.46Ca, and .sup.48Ca.

9. The method according to claim 2, wherein the method further comprises measuring the level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes in a blood sample or a tissue sample of the patient and diagnosing cancer in the patient if an increased level of at least one from the group consisting of sulfur isotopes, magnesium isotopes, silicon isotopes, calcium isotopes and iron isotopes is detected in the blood sample or tissue sample of the patient compared to a normal standard for the isotope.

10. The method according to claim 1, wherein the levels of deuterium .sup.2D and .sup.18O are measured and diagnosing cancer in the patient if the levels of the .sup.2D and .sup.18O isotope are greater than the level of a normal standard for the .sup.2D and .sup.18O isotope.